Peanut Oral Immunotherapy Study of Early Intervention for Desensitization
Peanut AllergyThe purpose of this study is to determine the efficacy and safety of AR101 in peanut-allergic children aged 1 to < 4 years.
ARTEMIS Peanut Allergy In Children
Peanut AllergyThe purpose of this study is to demonstrate the efficacy and safety of AR101 through oral immunotherapy (OIT) in peanut-allergic children.
Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut...
Peanut AllergyThis is a multi-center, randomized, double-blind placebo controlled study of efficacy and safety of characterized peanut oral immunotherapy in peanut allergic individuals.
Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy...
Peanut AllergyThe objectives of this dose-finding study for the treatment of peanut allergy are: To determine the efficacy of 3 doses of Viaskin Peanut (50 mcg ,100 mcg and 250 mcg peanut protein per patch) to significantly desensitize peanut-allergic subjects to peanut after 12 months of treatment. To evaluate the safety of a long-term treatment with Viaskin Peanut.
Peanut Allergy Oral Immunotherapy Desensitization
Peanut AllergyThe purpose of the study is to determine how a type of treatment for peanut allergy known as oral desensitization works in the immune system. Objectives To determine whether premedication with desloratidine and ranitidine results in fewer side effects during desensitization procedure. To assess quality of life in peanut allergic subjects before and after desensitization. To compare serum metabolites in peanut allergic and non peanut allergic subjects.
Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial
Peanut AllergyFood AllergyThe investigators will perform a double blind, placebo controlled clinical trial with Xolair (omalizumab) at four centers to safely and rapidly desensitize patients with severe peanut allergy. The investigators will determine if pretreatment with anti-IgE mAb (Xolair/omalizumab) can greatly reduce allergic reactions and allow for faster and safer desensitization.
Preventing Anaphylaxis With Acalabrutinib
Food AllergyFood Allergy PeanutFood allergy is a potentially life-threatening condition, and its prevalence continues to increase despite public health efforts. There are currently no known therapies that can reliably prevent food-induced anaphylaxis. This is an open-label study designed to determine the ability acalabrutinib to prevent signs and symptoms of anaphylaxis during an oral food challenge in food-allergic adults.
Peanut Oral Immunotherapy in Children
Peanut HypersensitivityThis is a randomized, double-blind, placebo-controlled, multi-center study comparing peanut oral immunotherapy (OIT) to placebo in the induction of tolerance and desensitization in peanut-allergic children. Eligible participants with peanut allergy will be randomly assigned to receive either peanut OIT or placebo for 134 weeks followed by peanut avoidance for 26 weeks.
Validation of the HYPONUT Product
Peanut AllergyThe HYPONUT product was previously validated in a laboratory setting ("Procédé de préparation d'aliment hypoallergénique", n° FR1250977) on 2012. A international patent was then obtained on 2013. Through the present study, the investigators would like to prove that the hypoallergenicity of the product is sustained in a clinical setting. Patients allergic to peanuts currently undergo in vivo tests to confirm their allergy: skin prick tests, and oral food challenges. In vitro tests are also performed (i.e. IgE levels for peanut and peanut components). The follow-up of patients consists in regular yearly or semestral evaluations. During one of these evaluation, the investigators will skin tests patients with the hyponut product to verify if they are sensitized to this last one as well. When skin tests will be negative, the investigators will propose to patients to take some of the product to verify its tolerability as well.
STEP-IT-UP - Peanut Allergy Study for Infants
Peanut AllergyFood AllergyMulticenter randomized (1:1) trial of strict avoidance versus sub-threshold dietary introduction of peanut in peanut allergic infants 4-14 months of age who react at a minimum cumulative dose of at least 430 mg of peanut protein at initial oral food challenge (OFC) for 12 months, followed by cross-over to sub-threshold dietary introduction of peanut in those randomized initially to avoidance.